Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.

This study is testing a combination of anlotinib (a targeted drug that cuts off blood supply to tumors) and whole-brain radiotherapy for people with small cell lung cancer (SCLC) that has spread to the brain. SCLC is an aggressive type of lung cancer, and brain metastases are a common complication. **You may be eligible if...** - You have small cell lung cancer confirmed by biopsy, with cancer that has spread to the brain - Your cancer is measurable on imaging scans - You have 10 or fewer brain tumors - Your life expectancy is more than 3 months - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have used anti-angiogenic drugs (blood supply-blocking drugs like anlotinib, bevacizumab) in the last month - Your diagnosis is non-small cell lung cancer - You have lung cancer with bleeding into the airways (hemoptysis) - You have had a recent stroke or brain bleed - You have previously received radiation to the brain - You have other life-threatening or severe uncontrolled health conditions Talk to your doctor to see if this trial is right for you.